Kawasaki syndrome: An intriguing disease with numerous unsolved dilemmas

Pediatric Rheumatology

Volumn 9, Issue , 2011, Pages

  Falcini, Fernanda ^a   Capannini, Serena ^a   Rigante, Donato ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CORTICOSTEROID; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; WARFARIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTERY INJURY; ATHEROSCLEROSIS; BLEEDING; CARDIOLOGIST; CHILD; CHILDHOOD DISEASE; CLINICAL EVALUATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONGENITAL HEART DISEASE; CORONARY ARTERY; DEVELOPED COUNTRY; DRUG DOSE REDUCTION; ETIOLOGY; FOLLOW UP; GOLD STANDARD; HUMAN; INCIDENCE; INFECTION; LABORATORY TEST; LONG TERM CARE; MEDICAL EDUCATION; MORBIDITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOLOGY; THROMBOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 79960561620     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-9-17     Document Type: Review

References (77)

1. Shulman ST, Rowley AH. Advances in Kawasaki disease. Eur J Pediatr 2004, 163:285-291. 10.1007/s00431-004-1431-z, 15346907.
2. Nakamura Y, Fujita Y, Nagai M, Yanagawa H, Imada Y, Okawa S, Kawasaki T, Kato H. Cardiac sequelae of Kawasaki disease in Japan: statistical analysis. Pediatrics 1991, 88:1144-1147.
3. Nakagawa N, Yoshida M, Narahara K, Kunitomi T. Kawasaki disease in an 8-day-old neonate. Pediatr Cardiol 2009, 30:527-529. 10.1007/s00246-008-9353-6, 19099172.
4. Marchetto S, Chiappini E, Simonini G, Falcini F, de Martino M. Lupus-like onset of recurrent Kawasaki disease in an adolescent boy. Clin Exp Rheumatol 2004, 22:377.
5. Gomard-Mennesson E, Landron C, Dauphin C, Epaulard O, Petit C, Green L, Roblot P, Lusson JR, Broussolle C, Sève P. Kawasaki disease in adults: report of 10 cases. Medicine (Baltimore) 2010, 89:149-158.
6. De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci 2007, 11:301-308.
7. Chang RK. Hospitalizations for Kawasaki disease among children in the United States,1988-1997. Pediatrics 2002, 109:e87. 10.1542/peds.109.6.e87, 12042581.
8. Ozen S, Ruperto N, Dillon MJ, Bagga A, Barron K, Davin JC, Kawasaki T, Lindsley C, Petty RE, Prieur AM, Ravelli A, Woo P. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006, 65:936-941. 1798210, 16322081.
9. Pannaraj PS, Turner CL, Bastian JF, Burns JC. Failure to diagnose Kawasaki disease at the extremes of the pediatric age range. Pediatr Infect Dis J 2004, 23:789-791. 10.1097/01.inf.0000134312.39744.a4, 15295237.
10. Nakamura Y, Yashiro M, Uehara R, Sadakane A, Chihara I, Aoyama Y, Kotani K, Yanagawa H. Epidemiologic features of Kawasaki disease in Japan: results of the 2007-2008 nationwide survey. J Epidemiol 2010, 20:302-307. 10.2188/jea.JE20090180, 20530917.
11. Hirata S, Nakamura Y, Yanagawa H. Incidence rate of recurrent Kawasaki disease and related risk factors: from the results of nationwide surveys of Kawasaki disease in Japan. Acta Paediatr 2001, 90:40-44. 10.1111/j.1651-2227.2001.tb00253.x, 11227331.
12. Dergun M, Kao A, Hauger SB, Newburger JW, Burns JC. Familial occurrence of Kawasaki syndrome in North America. Arch Pediatr Adolesc Med 2005, 159:876-881. 10.1001/archpedi.159.9.876, 2910318, 16143748.
13. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, Shulman ST, Bolger AF, Ferrieri P, Baltimore RS, Wilson WR, Baddour LM, Pallasch TJ, Falace DA, Taubert KA. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004, 110:2747-2771. 10.1161/01.CIR.0000145143.19711.78, 15505111.
14. Lee K-Y, Han JW, Lee J-S. Kawasaki disease may be a hyperimmune reaction of genetically susceptible children tovariants of normal environmental flora. Med Hypotheses 2007, 69:642-651. 10.1016/j.mehy.2006.12.051, 17337130.
15. Rowley AH, Baker SC, Shulman ST, Garcia FL, Fox LM, Kos IM, Crawford SE, Russo PA, Takahashi K, Orenstein JM. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS One 2008, 3:e1582. 10.1371/journal.pone.0001582, 2216059, 18270572.
16. Matsubara T, Farukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990, 56:29-36. 10.1016/0090-1229(90)90166-N, 2113446.
17. Hirao J, Hibi S, Andoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int Arch Allergy Immunol 1997, 112:152-156. 10.1159/000237447, 9030095.
18. Chan WC, Duong TT, Yeung RS. Presence of IFN-gamma does not indicate its necessity for induction of coronary arteritis in an animal model of Kawasaki disease. J Immunol 2001, 173:3492-3503.
19. Weng K-P, Hsieh K-S, Hwang Y-T, Huang S-H, Lai T-J, Yuh Y-S, Hou Y-Y, Lin C-C, Huang S-C, Chang C-K, Lin M-W, Ger L-P. IL-10 Polymorphisms are associated with coronary artery lesions in acute stage of Kawasaki disease. Circ J 2010, 74:983-989. 10.1253/circj.CJ-09-0801, 20339193.
20. Onouchi Y. Identification of susceptibility genes for Kawasaki disease. Jpn J Clin Immunol 2010, 33:73-80.
21. Yeung RS. Kawasaki disease: update on pathogenesis. Curr Opin Rheumatol 2010, 22:551-560. 10.1097/BOR.0b013e32833cf051, 20616737.
22. Shimizu C, Jain S, Davila S, Hibberd ML, Lin KO, Molkara D, Frazer JR, Sun S, Baker AL, Newburger JW, Rowley AH, Shulman ST, Davila S, Burgner D, Breunis WB, Kuijpers TW, Wright VJ, Levin M, Eleftherohorinou H, Coin L, Popper SJ, Relman DA, Fury W, Lin C, Mellis S, Tremoulet AH, Burns JC. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet 2011, 4:16-25. 10.1161/CIRCGENETICS.110.940858, 21127203.
23. Burgner D, Davila S, Breunis WB, Ng SB, Li Y, Bonnard C, Ling L, Wright WJ, Thalamuthu A, Odam M, Shimizu C, Burns JC, Levin M, Kuijpers TW, Hibberd ML. International Kawasaki Disease Genetics Consortium: A genome-wide association study identifies novel and functionally related susceptibility loci for Kawasaki disease. PLoS Genet 2009, 5:e1000319. 10.1371/journal.pgen.1000319, 2607021, 19132087.
24. Kim JJ, Hong YM, Sohn S, Jang GY, Ha KS, Yun SW, Han MK, Lee KY, Song MS, Lee HD, Kim DS, Lee JE, Shin ES, Jang JH, Lee YS, Kim SY, Lee JY, Han BG, Wu JY, Kim KJ, Park YM, Seo EJ, Park IS, Lee JK. Korean Kawasaki Disease Genetics Consortium. A genomewide association analysis reveals 1p31 and 2p13.3 as susceptibility loci for Kawasaki disease. Hum Genet 2011, 129:487-495. 10.1007/s00439-010-0937-x, 21221998.
25. Levy M, Koren G. Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J 1990, 9:122-126. 10.1097/00006454-199002000-00010, 2179838.
26. Yeo Y, Kim T, Ha K, Jang G, Lee J, Lee K, Son C, Lee J. Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor. Eur J Pediatr 2009, 168:157-162. 10.1007/s00431-008-0722-1, 18478263.
27. Genizi J, Miron D, Spiegel R, Fink D, Horovitz Y. Kawasaki disease in very young infants: high prevalence of atypical presentation and coronary arteritis. Clin Pediatr (Phila) 2003, 42:263-267.
28. Sonobe T, Kiyosawa N, Tsuchiya K, Aso S, Imada Y, Imai Y, Yashiro M, Nakamura Y, Yanagawa H. Prevalence of coronary artery abnormality in incomplete Kawasaki disease. Pediatr Int 2007, 49:421-426. 10.1111/j.1442-200X.2007.02396.x, 17587261.
29. Huang MY, Gupta-Malhotra M, Huang JJ, Syu FK, Huang TY. Acute-phase reactants and a supplemental diagnostic aid for Kawasaki disease. Pediatr Cardiol 2010, 31:1209-1213. 10.1007/s00246-010-9801-y, 20957478.
30. Printz BF, Sleeper LA, Newburger JW, Minich LL, Bradley T, Cohen MS, Frank D, Li JS, Margossian R, Shirali G, Takahashi M, Colan SD. Pediatric Heart Network Investigators. Noncoronary cardiac abnormalities are associated with coronary artery dilation and with laboratory inflammatory markers in acute Kawasaki disease. J Am Coll Cardiol 2010, 57:86-92.
31. Komatsu H, Tateno A. Failure to distinguish systemic-onset juvenile idiopathic arthritis from incomplete Kawasaki disease in an infant. J Paediatr Child Health 2007, 43:707-709. 10.1111/j.1440-1754.2007.01189.x, 17854457.
32. Burns JC, Mason WH, Glode MP, Shulman ST, Melish ME, Meissner C, Bastian J, Beiser AS, Meyerson HM, Newburger JW. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. J Pediatr 1991, 118:680-686. 10.1016/S0022-3476(05)80026-5, 2019921.
33. Crystal MA, Syan SK, Yeung RS, Dipchand AI, McCrindle BW. Echocardiographic and electrocardiographic trends in children with acute Kawasaki disease. Can J Cardiol 2008, 24:776-780. 10.1016/S0828-282X(08)70683-4, 2643158, 18841257.
34. Baker A, Neto LB, Newburger JW, DeMaso DR. Psychosocial concerns in children with Kawasaki disease. Progr Pediatr Cardiol 2004, 2:189-194.
35. Chalmers D, Corban JG, Moore PP. BCG site inflammation: a useful diagnostic sign in incomplete Kawasaki disease. J Paediatr Child Health 2008, 44:525-526.
36. Muta H, Ishii M, Furui J, Sugahara Y, Akagi T, Nakamura Y, Yanagawa H, Matsuishi T. Early intravenous γ-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004, 144:496-499. 10.1016/j.jpeds.2003.12.033, 15069399.
37. Tse SM, Silverman ED, Mc Crindle BW, Yeung RS. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease. J Pediatr 2002, 140:450-455. 10.1067/mpd.2002.122469, 12006960.
38. Nishihara S, Ishibashi K, Iribe K, Matsuda I. Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki disease. Lancet 1988, 2(8617):973..
39. Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, Kobayashi T, Morikawa A. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006, 113:2606-2612. 10.1161/CIRCULATIONAHA.105.592865, 16735679.
40. Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr 1997, 131:888-893. 10.1016/S0022-3476(97)70038-6, 9427895.
41. Uehara R, Belay ED, Maddox RA, Holman RC, Nakamura Y, Yashiro M, Oki I, Ogino H, Schonberger LB, Yanagawa I. Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan. Pediatr Infect Dis J 2008, 27:155-160.
42. Feigin RD, Barron KS. Treatment of Kawasaki syndrome. N Engl J Med 1986, 315:388-390. 10.1056/NEJM198608073150608, 2426593.
43. Newburger JW, Fulton DR. Kawasaki disease. Curr Treat Options Cardiovasc Med 2007, 9:148-158. 10.1007/s11936-007-0008-3, 17484817.
44. Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, Takeuchi K, Morikawa A. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr 2006, 149:336-341. 10.1016/j.jpeds.2006.05.025, 16939743.
45. Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, Atz AM, Li JS, Takahashi M, Baker AL, Colan SD, Mitchell PD, Klein GL, Sundel RP. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007, 356:663-675. 10.1056/NEJMoa061235, 17301297.
46. Adachi S, Sakagushi H, Kuwahara T, Uchida Y, Fukao T, Kondo N. High regression rate of coronary aneurysms developed in patients with immune globulin-resistant Kawasaki disease treated with steroid pulse therapy. Tohoku J Exp Med 2010, 220:285-290. 10.1620/tjem.220.285, 20410679.
47. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma-globulin retreatment in Kawasaki disease. J Pediatr 1993, 123:657-659. 10.1016/S0022-3476(05)80972-2, 8410524.
48. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gammaglobulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki disease Study Group. Pediatr Infect Dis J 1998, 17:1144-1148. 10.1097/00006454-199812000-00009, 9877364.
49. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996, 128:146-149. 10.1016/S0022-3476(96)70447-X, 8551407.
50. Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008, 93:142-146. 10.1136/adc.2007.126144, 17962370.
51. Dole RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr 2000, 137:723-726. 10.1067/mpd.2000.108444, 11060542.
52. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004, 31:808-810.
53. Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, Melish ME, Jackson MA, Asmar BI, Lang DJ, Connor JD, Capparelli EV, Keen ML, Mamun K, Keenan GTF, Ramilo O. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153:833-838. 10.1016/j.jpeds.2008.06.011, 2856847, 18672254.
54. Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, Watanabe K, Watanabe S, Uese K, Kanegane H, Origasa H, Ichida F, Roth J, Miyawaki T, Saji T. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009, 65:696-701. 10.1203/PDR.0b013e31819ed68d, 19430379.
55. Choueiter NF, Olson AK, Shen DD, Portman MA. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010, 157:960-966. 10.1016/j.jpeds.2010.06.014, 20667551.
56. Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporine A therapy. Pediatr Infect Dis 2001, 20:635-637.
57. Lee T, Kim K, Chun J-K, Kim D. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008, 49:714-718. 10.3349/ymj.2008.49.5.714, 2615375, 18972590.
58. Imagawa T, Mori M, Miyamae T, Ito S, Nakamura T, Yasui K, Kimura H, Yokota S. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004, 163:263-264. 10.1007/s00431-003-1267-y, 14986117.
59. Sugahara Y, Ishii M, Muta H, Iemura M, Matsuishi T, Kato H. Warfarin therapy for giant aneurysm prevents myocardial infarction in Kawasaki disease. Pediatr Cardiol 2008, 29:398-401. 10.1007/s00246-007-9132-9, 18027010.
60. Manlhiot C, Brandão LR, Somji Z, Chesney AL, MacDonald C, Gurofsky RC, Sabharwal T, Chahal N, McCrindle BW. Long-term anticoagulation in Kawasaki disease: initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities. Pediatr Cardiol 2010, 31:834-842. 10.1007/s00246-010-9715-8, 20431996.
61. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, Kazue T, Eto G, Yamakawa R. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996, 94:1379-1385.
62. Senzaki H. Long-term outcome of Kawasaki disease. Circulation 2008, 118:2763-2772. 10.1161/CIRCULATIONAHA.107.749515, 19106401.
63. Rowley A, Shulman ST. Pathogenesis and management of Kawasaki disease. Exp Rev Anti Infect Ther 2010, 8:197-203.
64. Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, Innocentini N, Zambetti C, Pancheri JM, Ostrow A, Frazer JR, Sundel RP, Fulton DR, Newburger JW. Performance of 2004 American Heart Associations recommendations for treatment of Kawasaki disease. Pediatrics 2010, 125:e234-241. 10.1542/peds.2009-0606, 2896313, 20100771.
65. Dhillon R, Clarkson P, Donald AE, Powe AJ, Nash M, Novelli V, Dillon MJ, Deanfield JE. Endothelial dysfunction late after Kawasaki disease. Circulation 1996, 94:2103-2106.
66. Niboshi A, Hamaoka K, Sakata K, Yamaguchi N. Endothelial dysfunction in adult patients with a history of Kawasaki disease. Eur J Pediatr 2008, 167:189-196. 10.1007/s00431-007-0452-9, 17345094.
67. Mitani Y, Ohashi H, Sawada H, Ikeyama Y, Hayakawa H, Takabayashi S, Maruyama K, Shimpo H, Komada Y. In vivo plaque composition and morphology in coronary artery lesions in adolescents and young adults long after Kawasaki disease: a virtual histology intravascular ultrasound study. Circulation 2009, 119:2829-2836. 10.1161/CIRCULATIONAHA.108.818609, 19451352.
68. Cheung YF, Yung TC, Tam SC, Ho MH, Chau AK. Novel and traditional cardiovascular risk factors in children after Kawasaki disease: implications for premature atherosclerosis. J Am Coll Cardiol 2004, 43:120-124. 10.1016/j.jacc.2003.08.030, 14715193.
69. McCrindle BW, McIntyre S, Kim C, Lin T, Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis?. J Pediatr 2007, 151:244-248. 10.1016/j.jpeds.2007.03.056, 17719931.
70. Kanamaru H, Karasawa K, Ichikawa R, Abe O, Miyashita M, Taniguchi K, Ayusawa M, Sumitomo N, Okada T, Takayama T, Sato Y, Saito S, Harada. Advantages of multislice spiral computed tomography for evaluation of serious coronary complications after Kawasaki disease. J Cardiol 2007, 50:21-27.
71. Arnold R, Ley S, Ley-Zaporozhan J, Eichhorn J, Schenk JP, Ulmer H, Kauczor HU. Visualization of coronary arteries in patients after childhood Kawasaki disease: value of multidetector CT and MR imaging in comparison to conventional coronary catheterization. Pediatr Radiol 2007, 37:998-1006. 10.1007/s00247-007-0566-2, 17768616.
72. Newburger JW, Fulton DR. Coronary revascularization in patients with Kawasaki disease. J Pediatr 2010, 157:8-10. 10.1016/j.jpeds.2010.04.008, 20472246.
73. Lang B, Duffy CM. Controversies in the management of Kawasaki disease. Best Pract Res Clin Rheumatol 2002, 16:427-442.
74. Miura M, Katada Y, Ishihara J. Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin. Eur J Pediatr 2004, 163:25-29. 10.1007/s00431-003-1335-3, 14624356.
75. Center KI, Hansen JR, Lewis E, Fireman BH, Hilton B. Lack of association of Kawasaki disease after immunization in a cohort of infants followed for multiple autoimmune diagnoses in a large, phase-4 observational database safety study of 7-valent pneumococcal conjugate vaccine: lack of association between Kawasaki disease and seven-valent pneumococcal conjugate vaccine. Pediatric Infect Dis J 2009, 28:438-440.
76. Hua W, Izurieta HS, Slade B, Belay ED, Haber P, Tiernan R, Woo EJ, Iskander J, Braun MM, Ball R. Kawasaki disease after vaccination: reports to the vaccine adverse events reporting system. Pediatr Infect Dis J 2009, 28:943-947. 10.1097/INF.0b013e3181a66471, 19755926.
77. Miron D, Fink D, Hashkes PJ. Kawasaki disease in an infant following immunization with hepatitis B vaccine. Clin Rheumatol 2003, 22:461-463. 10.1007/s10067-003-0785-3, 14677029.